The FDA has resumed posting complete response letters (CRLs), adding another batch of rejection notices as regulators emphasize “commitment to transparency.” The latest wave includes multiple pharma programs, including the Hengrui–Elevar liver cancer combination receiving repeated scrutiny tied to manufacturing issues. In separate reporting, FDA posted additional CRLs after a period in which HHS confirmed a pause on new CRL releases, making the sequence of letters a key near-term signal for development timelines and filing strategies. For companies relying on accelerated regulatory feedback loops, CRL volume can materially affect risk assessments for late-stage trial execution and commercial launch planning. For the liver cancer program, multiple rejections highlight how manufacturing deficiencies can become the dominant variable even when clinical rationales remain intact.